期刊
CURRENT OPINION IN VIROLOGY
卷 32, 期 -, 页码 60-70出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2018.08.014
关键词
-
类别
资金
- Biotechnology and Biological Sciences Research Council [BB/M006557/1, BB/N014405/1]
- Medical Research Council [MR/R010145/1, 95505168]
- Worldwide Cancer Research [16-1025]
- Wellcome Trust [203826/Z/16/Z]
- Rosetrees Trust [M662]
- BBSRC [BB/M006557/1, BB/N014405/1] Funding Source: UKRI
- MRC [1942169, MR/R010145/1] Funding Source: UKRI
- Wellcome Trust [203826/Z/16/Z] Funding Source: Wellcome Trust
- Biotechnology and Biological Sciences Research Council [BB/N014405/1] Funding Source: researchfish
Kaposi's Sarcoma-associated herpesvirus (KSHV) and Epstein Barr virus (EBV) are the causative agents of several malignancies. Like all herpesviruses, KSHV and EBV undergo distinct latent and lytic replication programmes. The transition between these states allows the establishment of a lifelong persistent infection, dissemination to sites of disease and the spread to new hosts. Latency-associated viral proteins have been well characterised in transformation and tumourigenesis pathways; however, a number of studies have shown that abrogation of KSHV and EBV lytic gene expression impairs the oncogenesis of several cancers. Furthermore, several lytically expressed proteins have been functionally tethered to the angioproliferative and anti-apoptotic phenotypes of virus infected cells. As a result, the investigation and therapeutic targeting of KSHV and EBV lytic cycles may be essential for the treatment of their associated malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据